by Gary Cooke | Nov 27, 2019 | News
Dr Vickie Driver appointed Executive Vice President, Global Head of Tissue Repair & Regenerative Medicine Thirty Group announces the appointment of Dr. Vickie Driver as Executive Vice President, Global Head of Tissue Repair & Regenerative Medicine. Dr. Driver... by Gary Cooke | Nov 20, 2019 | News
BEN FENBY APPOINTED CHIEF DEVELOPMENT OFFICER Dr Ben Fenby joins Thirty Group as Chief Development Officer, effective Jan 6, 2020, from an oncology biotech where he was responsible for the late stage portfolio development and strategy. Prior to this Ben worked at... by Gary Cooke | Oct 4, 2019 | News
Thirty Group launches 30Innovation and completes first transaction Thirty Holdings announces the formation of 30Innovation, a wholly owned subsidiary to advance early stage research in biomaterial innovation and new modalities to harness 30Technology™ across... by Gary Cooke | Jun 25, 2019 | News
New 30Technology Research Centre opens in Oxford Thirty Group is delighted to announce the opening of its new Research Centre at Milton Park, Oxford. The facility will house clinical, research, development and regulatory activities for our revolutionary... by 30 Technology | Nov 1, 2018 | News
MORNINGSIDE VENTURES INVESTS IN THIRTY HOLDINGS Thirty Holdings Limited completed a £25 million equity investment led by Morningside Ventures, a major investor in the global Life Science sector. The investment enables the Group to accelerate research and development.... by 30 Technology | Oct 1, 2018 | News
A NEW NAME FOR A NEW ERA Thirty Holdings Limited established following a corporate restructure. The Company trading name will be 30 Technology with the name derived from the molecular weight of nitric oxide (30). Edixomed Limited is now a wholly owned subsidiary of...
Recent Comments